Sentien Biotechnologies, Inc. Announces Initial Round of Financing

In News

Sentien Biotechnologies, Inc., a regenerative medicine company developing cell based therapies for acute organ failure, is pleased to announce an initial round of financing by Boehringer Ingelheim Venture Fund USA, Inc. and Portage Biotech Inc. Learn more here.